Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial

BACKGROUND: Dipeptidyl peptidase-4 inhibitors (DPP-4i) have become firmly established in treatment algorithms and national guidelines for improving glycemic control in type 2 diabetes mellitus (T2DM).To report the findings from a multicenter, randomized, double-blind, placebo-controlled phase 3 clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Mingtong, Sun, Kan, Xu, Wenjie, Wang, Chuan, Yan, Dewen, Li, Shu, Cong, Li, Pi, Yinzhen, Song, Weihong, Sun, Qingyuan, Xiao, Rijun, Peng, Weixia, Wang, Jianping, Peng, Hui, Zhang, Yawei, Duan, Peng, Zhang, Meiying, Liu, Jianying, Huang, Qingmei, Li, Xuefeng, Bao, Yan, Zeng, Tianshu, Wang, Kun, Qin, Li, Wu, Chaoming, Deng, Chunying, Huang, Chenghu, Yan, Shuang, Zhang, Wei, Li, Meizi, Sun, Li, Wang, Yanjun, Li, HongMei, Wang, Guang, Pang, Shuguang, Zheng, Xianling, Wang, Haifang, Wang, Fujun, Su, Xiuhai, Ma, Yujin, Li, Ziling, Xie, Zuoling, Xu, Ning, Ni, Lin, Zhang, Li, Deng, Xiangqun, Pan, Tianrong, Dong, Qijuan, Wu, Xiaohong, Shen, Xingping, Zhang, Xin, Zou, Qijing, Jiang, Chengxia, Xi, Jue, Ma, Jianhua, Sun, Jingchao, Yan, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563289/
https://www.ncbi.nlm.nih.gov/pubmed/37814306
http://dx.doi.org/10.1186/s12916-023-03089-x

Ejemplares similares

Ejemplares similares